{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:40:04Z","timestamp":1785800404839,"version":"3.56.0"},"reference-count":179,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Synthesized more than 60 years ago, vinpocetine\u2014the active ingredient of Cavinton\u00ae, with over five decades of clinical use\u2014has remained the subject of extensive investigation, particularly during the past 15 years. During this time, a large body of experimental preclinical evidence has accumulated demonstrating its neuroprotective potential and complex mechanisms of action in cerebral ischemia\u2013hypoxia. Comprehensive in vitro studies and animal experiments have significantly elucidated the molecular basis of vinpocetine and the signaling pathways through which it prevents or mitigates ischemic injury. In this review, we summarize earlier and more recent experimental results that highlight the multifaceted nature of vinpocetine\u2019s neuroprotective actions, which include inhibition of phosphodiesterase type 1, blockade of voltage-dependent NaV1.8 channels, reduction of oxidative stress, and suppression of neuroinflammatory processes triggered by cerebral ischemia\u2013hypoxia. Taken together, it can be hypothesized that, under in vivo conditions, vinpocetine\u2019s individual actions are additive or synergistic, thereby contributing in a combined manner to recovery from cerebral ischemic insult.<\/jats:p>","DOI":"10.3390\/biom16030454","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:20:14Z","timestamp":1773764414000},"page":"454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vinpocetine\u2014An \u201cOld\u201d Drug with a New Face: Moving Toward a Better Understanding of Its Neuroprotective Mechanism of Action"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-4597","authenticated-orcid":false,"given":"E. Sylvester","family":"Vizi","sequence":"first","affiliation":[{"name":"HUN-REN Institute of Experimental Medicine, Szigony-u 43, H-1083 Budapest, Hungary"},{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyv\u00e1rad t\u00e9r 4, H-1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Kiss","sequence":"additional","affiliation":[{"name":"Gedeon Richter Plc, Gy\u00f6mr\u0151i u, 19-21, H-1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s10787-024-01529-5","article-title":"Atheroprotective role of vinpocetine: An old drug with new indication","volume":"32","author":"Alexiou","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12950-024-00394-x","article-title":"The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis","volume":"21","author":"Alshehri","year":"2024","journal-title":"J. Inflamm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s11011-023-01254-y","article-title":"New insights on the potential effect of vinpocetine in Parkinson's disease: One of the neglected warden and baffling topics","volume":"38","author":"Alexiou","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Puig, N., Sol\u00e9, A., Aguilera-Simon, A., Gri\u00f1\u00e1n, R., Rotllan, N., Camps-Renom, P., and Benitez, S. (2023). Novel therapeutic approaches to prevent atherothrombotic ischemic stroke in patients with carotid atherosclerosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814325"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Li, Y., Cui, R., Liu, S., Qin, Z., Sun, W., Cheng, Y., and Liu, Q. (2023). The efficacy and safety of post-stroke cognitive impairment therapies: An umbrella review. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1207075"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12950-023-00330-5","article-title":"Anti-inflammatory therapy of atherosclerosis: Focusing on IKK\u03b2","volume":"20","author":"Gan","year":"2023","journal-title":"J. Inflamm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12028-022-01499-y","article-title":"Safety and efficacy of vinpocetine as a neuroprotective agent in acute ischemic stroke: A systematic review and meta-analysis","volume":"37","author":"Panda","year":"2022","journal-title":"Neurocrit. Care"},{"key":"ref_8","first-page":"13","article-title":"Vinpocetine\u2019s immunomodulating, antioxidant, anti-inflammatory, anti-fibrotic, and PDE inhibiting potencies ameliorate bleomycin-induced pulmonary fibrosis","volume":"26","author":"Balaha","year":"2023","journal-title":"Iran. J. Basic Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sheng, J., Zhang, S., Wu, L., Kumar, G., Liao, Y., GK, P., and Fan, H. (2022). Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer\u2019s disease. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.1019187"},{"key":"ref_10","first-page":"1","article-title":"Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review","volume":"6","author":"Naji","year":"2020","journal-title":"Brain Circ."},{"key":"ref_11","first-page":"211","article-title":"Updates of recent vinpocetine research in treating cardiovascular diseases","volume":"2","author":"Zhang","year":"2020","journal-title":"J. Cell. Immunol."},{"key":"ref_12","first-page":"6590","article-title":"Review on vinpocetine","volume":"11","author":"Dubey","year":"2020","journal-title":"Int. J. Pharm. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel Phosphodiesterase Inhibitors for cognitive Improvement in Alzheimer's disease. Miniperspective","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejphar.2017.11.041","article-title":"An update on vinpocetine: New discoveries and clinical implications","volume":"819","author":"Zhang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Knott, R., Assi, M., Rao, S.N.R., Ghosh, M., and Pearse, D.P. (2017). Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040696"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1042\/CS20150605","article-title":"Cyclic nucleotide phosphodiesterase 1 and vascular aging","volume":"129","author":"Yan","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/molecules20010335","article-title":"Anti-Inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: A review of the literature","volume":"20","author":"Zhang","year":"2015","journal-title":"Molecules"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S1734-1140(11)70574-6","article-title":"Role of vinpocetine in cerebrovascular diseases","volume":"63","author":"Patyar","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Foyaca-Sibat, H. (2011). Antiepileptic drugs targeting cerebral presynaptic ion channels reduce cerebral excitability decreasing glutamate release. Novel Treatment of Epilepsy, InTech.","DOI":"10.5772\/735"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.1073\/pnas.1005138107","article-title":"Vinpocetine as a potent antiinflammatory agent","volume":"107","author":"Medina","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1073\/pnas.0914414107","article-title":"Vinpocetine inhibits NF-\u03baB\u2013dependent inflammation via an IKK-dependent but PDE-independent mechanism","volume":"107","author":"Jeon","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","first-page":"CD000480","article-title":"Vinpocetine for acute ischaemic stroke","volume":"2008","author":"Bereczki","year":"2008","journal-title":"Cohrane Database Syst. Rev."},{"key":"ref_25","first-page":"CD003119","article-title":"Vinpocetine for cognitive impairment and dementia","volume":"2003","author":"Whitehouse","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-510X(02)00301-5","article-title":"Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: A summary of evidences","volume":"203\u2013204","author":"Vas","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"ref_27","first-page":"84","article-title":"A vinpocetin neuroprotekt\u00edv hat\u00e1sai in vivo \u00e9s in vitro","volume":"72","author":"Nagy","year":"2002","journal-title":"Acta Pharmaceutica Hungarica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0361-9230(00)00354-3","article-title":"Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine","volume":"53","author":"Nemes","year":"2000","journal-title":"Brain Res. Bull."},{"key":"ref_29","first-page":"1907","article-title":"The synthesis of ethyl apovincaminate","volume":"26","author":"Kisfaludi","year":"1976","journal-title":"Arzneim. Forsch."},{"key":"ref_30","first-page":"198530n","article-title":"Preparation of apovincaminic acid esters","volume":"98","author":"Kalaus","year":"1983","journal-title":"Ger. Pat. Chem. Abstr."},{"key":"ref_31","first-page":"1909","article-title":"General and cerebral hemodynamic activity of ethyl apovincaminate","volume":"26","author":"Szporny","year":"1986","journal-title":"Arzneim. Forsch."},{"key":"ref_32","first-page":"1918","article-title":"Protective activity of ethyl apovincaminate on ischaemic anoxia of brain","volume":"26","author":"Szporny","year":"1976","journal-title":"Arzneim. Forsch."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1254\/fpj.80.225","article-title":"Protective effect of vinpocetine on experimental brain ischemia","volume":"80","author":"Kakihana","year":"1982","journal-title":"Folia Pharmacol. Jpn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ddr.430090307","article-title":"Comparison of the effects of vinpocetine, vincamine, phenytoin, and cinnarizine in a rat model of cerebral ischemia","volume":"9","author":"King","year":"1986","journal-title":"Drug Dev. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ddr.430140322","article-title":"Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia","volume":"14","author":"Lamar","year":"1988","journal-title":"Drug Dev. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ddr.430150108","article-title":"Comparison of the effect of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats","volume":"15","author":"Szporny","year":"1988","journal-title":"Drug Dev. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/0024-3205(88)90485-7","article-title":"Vinpocetine prevents ischemic cell damage in rat hippocampus","volume":"43","author":"Sauer","year":"1988","journal-title":"Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0021-5198(19)40125-X","article-title":"Carbon monoxide (CO)-induced hypoxia in mice: Evaluation as an experimental model of cerebral ischemia for drug screening","volume":"51","author":"Koida","year":"1989","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_39","first-page":"349","article-title":"Effect of various classes of drugs on complete ischemia induced by decapitation and cyanide intoxication in mice","volume":"10","author":"Araki","year":"1988","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0021-5198(19)39861-0","article-title":"Protective effect of vinpocetine against brain damage caused by ischemia","volume":"56","author":"Rischke","year":"1991","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.fct.2010.12.015","article-title":"Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture","volume":"49","author":"Solanki","year":"2011","journal-title":"Food Chem. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000138712","article-title":"Effects of vinpocetine on local cerebral blood flow and glucose utilization 7 days after forebrain ischemia in the rat","volume":"41","author":"Rischke","year":"1990","journal-title":"Pharmacology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0929-8266(02)00006-X","article-title":"Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: A near infrared spectroscopy and transcranial Doppler study","volume":"15","author":"Nagy","year":"2002","journal-title":"Eur. J. Ultrasound"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.exer.2016.11.018","article-title":"Pre-treatment with vinpocetine protects against retinal ischemia","volume":"154","author":"Khoo","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1139\/cjpp-2013-0097","article-title":"Vinpocetine protects liver against ischemia-reperfusion injury","volume":"91","author":"Zaki","year":"2013","journal-title":"Canad. J. Physiol. Pharmacol."},{"key":"ref_46","first-page":"2380","article-title":"Effects of vinpocetine on renal ischemia reperfusion injury in a male rat model","volume":"11","author":"Abbas","year":"2020","journal-title":"Sys. Rev. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e23046","DOI":"10.1002\/jbt.23046","article-title":"Renoprotective effect of vinpocetine against ischemia\/reperfusion injury: Modulation of NADPH oxidase\/Nrf2, IKK\u00df\/NF-\u03baB p65, and cleaved caspase-3 expressions","volume":"36","author":"Azouz","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"126472","DOI":"10.1016\/j.bmcl.2019.05.052","article-title":"Synthesis and biological evaluation of vinpocetine derivatives","volume":"30","author":"Pan","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dong, Z.-C., Shi, Y., Zheng, L.-L., Tian, Y.-P., Yang, J., Wei, Y., Zhou, Y., and Pan, B.-W. (2023). Synthesis and activity evaluation of vinpocetine-derived indole alkaloids. Molecules, 29.","DOI":"10.3390\/molecules29010014"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1039\/D3RA07325D","article-title":"Synthesis and pharmacological activity of vinpocetine derivatives","volume":"14","author":"Dong","year":"2024","journal-title":"RSC Adv."},{"key":"ref_51","first-page":"1926","article-title":"Biochemical effects of ethyl apovincaminate","volume":"26","author":"Rosdy","year":"1976","journal-title":"Arzneim. Forsch."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/0006-2952(89)90631-X","article-title":"Effects of selective inhibitors on cyclic nucleotide phosphodiesterase of rabbit aorta","volume":"38","author":"Ahn","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/ajh\/1.3.262","article-title":"Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta","volume":"1","author":"Chiu","year":"1988","journal-title":"Am. J. Hypertens."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0006-2952(84)90240-5","article-title":"Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle","volume":"33","author":"Hagiwara","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"25699","DOI":"10.1074\/jbc.271.41.25699","article-title":"The calmodulin-dependent phosphodiesterase gene PDE1c encodes several functionally different splice variants in a tissue-specific manner","volume":"271","author":"Yan","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1476-5381.1989.tb14599.x","article-title":"Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions M & B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine","volume":"98","author":"Souness","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(96)00542-0","article-title":"Vincamine and vincanol are potent blockers of voltage gated-sodium channels","volume":"314","author":"Lakics","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(94)00755-V","article-title":"Vinpocetine is as potent as phenytoin to block voltage-gated Na+-channels in rat cortical neurons","volume":"273","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","first-page":"219","article-title":"11C.vinpocetine: A prospective peripheral benzodiazepine receptor ligand for primate PET studies","volume":"229","author":"Halldin","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0922-4106(90)90229-Q","article-title":"The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: Effects of bifemelane and several nootropic drugs","volume":"189","author":"Kaneko","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/00001756-199806010-00034","article-title":"The neuroprotective drug vinpocetine prevents veratridine-induced Na+ i and Ca2+ i rise in synaptosomes","volume":"9","author":"Tretter","year":"1998","journal-title":"Neuroreport"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ddr.430140319","article-title":"Effect of vinpocetine on monoamine receptor binding and synaptosomal uptake in the rat brain","volume":"14","author":"Lee","year":"1988","journal-title":"Drug Dev. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/medicines2020093","article-title":"Studies on pharmacokinetic drug interaction potential of vinpocetine","volume":"2","author":"Manda","year":"2015","journal-title":"Medicines"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113125","DOI":"10.1016\/j.biopha.2022.113125","article-title":"Glutamate excitot oxicity: Potential therapeutic target for ischemic stroke","volume":"151","author":"Shen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jurcau, A., and Simion, A. (2022). Neuroinflammation in cerebral ischemia and ischemia\/reperfusion injuries: From pathophysiology to therapeutic strategies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010014"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s12264-022-00859-0","article-title":"Neuronal death mechanisms and therapeutic strategy in ischemic stroke","volume":"38","author":"Mao","year":"2022","journal-title":"Neurosci. Bull."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"121814","DOI":"10.1016\/j.lfs.2023.121814","article-title":"Molecular mechanisms of ischemia and glutamate excitotoxicity","volume":"328","author":"Neves","year":"2023","journal-title":"Life Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6687386","DOI":"10.1155\/2021\/6687386","article-title":"Neuroprotective phytochemicals in experimental ischemic stroke: Mechanisms and potential clinical applications","volume":"2021","author":"Xu","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0014-2999(90)90386-K","article-title":"Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex","volume":"187","author":"Cai","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-2999(91)90019-M","article-title":"Vinpocetine preferentially antagonizes quisqualate\/AMPA receptor responses: Evidence from release and ligand binding studies","volume":"209","author":"Kiss","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eplepsyres.2011.06.006","article-title":"Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs","volume":"96","author":"Sitges","year":"2011","journal-title":"Epilepsy Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.neuropharm.2006.09.002","article-title":"Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of 3H.glutamate in hippocampal nerve endings","volume":"52","author":"Sitges","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1755-5949.2009.00078.x","article-title":"Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model","volume":"15","author":"Nyakas","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lenkey, N., K\u00e1roly, R., Luk\u00e1cs, P., Vizi, E.S., Sunesen, M., Fodor, L., and Mike, \u00c1. (2010). Classification of drugs based on properties of sodium channel inhibition: A comparative automated patch-clamp study. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015568"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/156802609788317856","article-title":"Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential","volume":"9","author":"Zuliani","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.neuroscience.2004.02.036","article-title":"A novel modulatory mechanism of sodium currents: Frequency-dependence without state-dependent binding","volume":"125","author":"Mike","year":"2004","journal-title":"Neuroscience"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nbt1194","article-title":"Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential","volume":"24","author":"Huang","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11159","article-title":"Large-scale prediction and testing of drug activity on side-effect targets","volume":"486","author":"Lounkine","year":"2012","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/00001756-200310270-00013","article-title":"Inhibitory effect of the DA uptake blocker GBR 12909 on sodium channels of hippocampal neurons","volume":"14","author":"Mike","year":"2003","journal-title":"Neuroreport"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1540-8167.2011.02098.x","article-title":"Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: Preliminary results","volume":"22","author":"Cakulev","year":"2011","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1540-8167.2009.01622.x","article-title":"Vanoxerine, a new drug for terminating atrial fibrillation and flutter","volume":"21","author":"Matsumoto","year":"2010","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1038\/s41598-018-26444-y","article-title":"Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog","volume":"8","author":"Lukacs","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bph.15365","article-title":"The mechanism of non-blocking inhibition of sodium channels revealed by conformational-selective photolabeling","volume":"178","author":"Pesti","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e2309773120","DOI":"10.1073\/pnas.2309773120","article-title":"Dual-pocket inhibition of Nav channels by antiepileptic drug lamotrigine","volume":"120","author":"Huang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1038\/s41467-024-52539-4","article-title":"Structural basis for the rescue of hyperexcitable cells by the amyotrophic lateral sclerosis drug riluzole","volume":"15","author":"Hollingworth","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e202413658","DOI":"10.1085\/jgp.202413658","article-title":"Drugs exhibit diverse binding modes and access routes in the Nav1.5 cardiac sodium channel pore","volume":"157","author":"Tao","year":"2025","journal-title":"J. Gen. Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3940(94)11241-A","article-title":"Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary culture of rat cerebral cortex","volume":"185","author":"Lakics","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_88","first-page":"89","article-title":"Protection against veratrine toxicity in rat cortical cultures: Relationship to sodium channel blockade","volume":"7","author":"Lakics","year":"1995","journal-title":"Neuroreport"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1023\/A:1012365408215","article-title":"The nootropic drug vinpocetine inhibits veratridine-induced Ca2+.i increase in rat hippocampal CA1 pyramidal cells","volume":"26","author":"Zelles","year":"2001","journal-title":"Neurochem. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1021164418478","article-title":"Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation","volume":"24","author":"Sitges","year":"1999","journal-title":"Neurochem. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.051086","article-title":"Vinpocetine is a potent blocker of rat Nav1.8 tetrodotoxin-resistant sodium channels","volume":"306","author":"Zhou","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_92","first-page":"1279","article-title":"Neuroprotective effect of sodium channel blockers in ischemia: The pathomechanism of early ischemic dysfunction","volume":"141","year":"2000","journal-title":"Orv. Hetil."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuint.2005.12.019","article-title":"Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na+, Ca2+ and glutamate release in hippocampal isolated nerve endings","volume":"49","author":"Sitges","year":"2006","journal-title":"Neurochem. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41467-023-38942-3","article-title":"Structural mapping of Nav1.7 antagonists","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0361-9230(02)00873-0","article-title":"A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2\/3 pyramidal cells","volume":"59","author":"Lendvai","year":"2003","journal-title":"Brain Res. Bull."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective Nav1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-024-00203-3","article-title":"NaV1.8 inhibitor poised to provide opioid-free pain relief","volume":"24","author":"Kingwell","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0028-3908(94)90141-4","article-title":"Role of NMDA, AMPA and kainate receptors in mediating glutamate- and 4-AP-induced dopamine and acetylcholine release from rat striatal slices","volume":"33","author":"Jin","year":"1994","journal-title":"Neuropharmacology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01252021","article-title":"The effect of 4-aminopyridine on acetylcholine release","volume":"41","author":"Vizi","year":"1977","journal-title":"J. Neural Transm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuint.2005.02.001","article-title":"Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes","volume":"46","author":"Sitges","year":"2005","journal-title":"Neurochem. Internatl."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neulet.2006.07.042","article-title":"Additive effects of antiepileptic drugs and pentylenetetrazole on hearing","volume":"406","author":"Nekrassov","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/jpp\/rgab011","article-title":"New insights into the effects of vinpocetine against neurobehavioral comorbidities in a rat model of temporal lobe epilepsy via the downregulation of the hippocampal PI3K\/mTOR signalling pathway","volume":"73","author":"Salem","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jare.2023.11.022","article-title":"An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds","volume":"64","author":"Zhao","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1358\/dot.2010.46.4.1445795","article-title":"Recent advances in adjunctive therapy for epilepsy: Focus on sodium channel blockers as third generation antiepileptic drugs","volume":"46","author":"Vohora","year":"2010","journal-title":"Drugs Today"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"107988","DOI":"10.1016\/j.yebeh.2021.107988","article-title":"Vinpocetine, cognition, and epilepsy","volume":"119","author":"Meador","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/epi.16394","article-title":"Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation","volume":"60","author":"Billakota","year":"2019","journal-title":"Epilepsia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/acn3.51838","article-title":"Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant","volume":"10","author":"Gjerulfsen","year":"2023","journal-title":"Ann. Clin. Translat. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wu, L., Xiong, X., Wu, X., Ye, Y., Jian, Z., Zhi, Z., and Gu, L. (2020). Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury. Front. Mol. Neurosci., 13.","DOI":"10.3389\/fnmol.2020.00028"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8624318","DOI":"10.1155\/2022\/8624318","article-title":"Therapeutic targets for regulating oxidative damage induced by ischemia-reperfusion injury: A study from a pharmacological perspective","volume":"2022","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_110","first-page":"309","article-title":"An in vitro study of the hydroxyl scavenger effect of Cavinton","volume":"30","author":"Balla","year":"1990","journal-title":"Acta Pediatr. Hung."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002826-200201000-00007","article-title":"In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine","volume":"25","author":"Marton","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10715760000300061","article-title":"Synaptosomal response to oxidative stress: Effect of vinpocetine","volume":"32","author":"Santos","year":"2000","journal-title":"Free. Radic. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jnc.12082","article-title":"Vinpocetine and \u03b1-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings","volume":"124","author":"Sitges","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0022-3565(25)22783-5","article-title":"Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line","volume":"250","author":"Miyamoto","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_115","first-page":"324307","article-title":"Vinpocetine and pyritinol: A new model for blood rheological modulation in cerebrovascular disorders-a randomized controlled clinical study","volume":"2014","author":"Albuhadilly","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s11064-019-02871-9","article-title":"The mitochondrial targets of neuroprotective drug vinpocetine on primary neuron cultures, brain capillary endothelial cells, synaptosomes, and brain mitochondria","volume":"44","author":"Svab","year":"2019","journal-title":"Neurochem. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10715760000301041","article-title":"Vinpocetine attenuates the metabolic dysfunction induced by amyloid \u00df-peptides in PC12 cells","volume":"33","author":"Pereira","year":"2000","journal-title":"Free Radic. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s11064-011-0450-1","article-title":"Oxidative stress in a model of toxic demyelination in rat brain: The effect of piracetam and vinpocetine","volume":"36","author":"Khadrawy","year":"2011","journal-title":"Neurochem. Res."},{"key":"ref_119","first-page":"6481812","article-title":"Repurposing of the nootropic drug vinpocetine as an analgesic and anti-inflammatory agent: Evidence in a mouse model of superoxide anion-triggered inflammation","volume":"2019","author":"Fattori","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ruiz-Miyazawa, K.W., Zarpelon, A.C., Pinho-Ribeiro, F.A., Pavao-de-Souza, G.F., Casgrande, R., and Veri, W.A. (2015). Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-\u03baB activation in the paw and spinal cord. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118942"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cbi.2015.05.007","article-title":"Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-kB","volume":"237","author":"Zarpelon","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.20517\/2347-8659.2017.09","article-title":"Role of neuroinflammation in ischemic stroke","volume":"4","author":"Liu","year":"2017","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12974-019-1516-2","article-title":"Neuroinflammation: Friend and foe for ischemic stroke","volume":"16","author":"Jayraj","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Stuckey, S.M., Ong, L.K., Collins-Praino, L.E., and Turner, R.J. (2021). Neuroinflammation as a key driver of secondary neurodegeneration following stroke. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313101"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Levinson, S., Pulli, B., and Heit, J.J. (2025). Neuroinflammation and acute ischemic stroke: Impact on translational research and clinical care. Front. Surg., 12.","DOI":"10.3389\/fsurg.2025.1501359"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0031-6997(24)01470-4","article-title":"The sympathetic nerve--an integrative interface between two supersystems: The brain and the immune system","volume":"52","author":"Elenkov","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2023.05.021","article-title":"Neuroprotective effects of vinpocetine against ischemia-reperfusion injury via inhibiting NLRP3 inflammasome signaling pathway","volume":"526","author":"Hou","year":"2023","journal-title":"Neuroscience"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jocn.2013.07.039","article-title":"Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia","volume":"21","author":"Wang","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neulet.2014.02.045","article-title":"Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia-reperfusion injury","volume":"566","author":"Wang","year":"2014","journal-title":"Neurosci. Lett."},{"key":"ref_130","first-page":"172","article-title":"Vinpocetine inhibits NF-\u03baB-dependent inflammation in acute ischemic stroke patients","volume":"9","author":"Zhang","year":"2017","journal-title":"Transl. Stroke Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"80315","DOI":"10.18632\/oncotarget.20699","article-title":"Vinpocetine alleviate cerebral ischemia\/reperfusion injury by down-regulating TLR4\/MyD88\/NF-\u03baB signaling","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Zhao, M., Hou, S., Feng, L., Shen, P., Nan, D., Zhang, Y., Wang, F., Ma, D., and Feng, J. (2020). Vinpocetine protects against cerebral ischemia-reperfusion injury by targeting astrocytic connexin43 via the PI3K\/AKT signaling pathway. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00223"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Zagrean, A.M., Hermann, D.M., Opris, I., Zagrean, L., and Popa-Wagner, A. (2018). Multicellular crosstalk between exosomes and the neurovascular unit after cerebral ischemia. Therapeutic implications. Front. Neurosci., 12.","DOI":"10.3389\/fnins.2018.00811"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Zang, J., Wu, J., Su, X., Zhang, T., Tang, X., Ma, D., Li, Y., Weng, Z., Liu, X., and Tsan Kwan, C.K. (2021). Inhibition of PDE1-B by vinpocetine regulates microglial exosomes and polarization through enhancing autophagic flux for neuroprotection against ischemic stroke. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.616590"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1007\/s12035-024-04515-8","article-title":"Vinpocetine ameliorates neuronal injury after cold-induced traumatic brain injury in mice","volume":"2","author":"Yelkenci","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2147\/JIR.S461795","article-title":"Microglia in ischemic stroke: Pathogenesis insights and therapeutic challenges","volume":"17","author":"Shui","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1740925X12000129","article-title":"TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation","volume":"7","author":"Zhao","year":"2011","journal-title":"Neuron Glia Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0161-813X(02)00004-9","article-title":"Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation","volume":"23","author":"Gabryel","year":"2002","journal-title":"Neurotoxicology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","article-title":"Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation","volume":"14","author":"Polli","year":"1994","journal-title":"J. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0090-4295(99)80103-4","article-title":"Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: Characterisation and functional effects of various phosphodiesterase inhibitors in vitro","volume":"45","author":"Truss","year":"1995","journal-title":"Urology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cellsig.2004.12.017","article-title":"Ca2+-calmodulin-dependent phosphodiesterase (PDE1): Current perspectives","volume":"17","author":"Goraya","year":"2005","journal-title":"Cell. Signal."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.9758\/cpn.24.1229","article-title":"In the brain of phosphodiesterases: Potential therapeutic targets for schiophrenia","volume":"23","author":"Barbagallo","year":"2025","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1078580","DOI":"10.1016\/j.pharmthera.2021.107858","article-title":"Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities","volume":"226","author":"Samidurai","year":"2021","journal-title":"Pharmacol. Therap."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"110251","DOI":"10.1016\/j.cellsig.2022.110251","article-title":"Phosphodiesterase-1 in the cardiovascular system","volume":"92","author":"Roks","year":"2022","journal-title":"Cell. Signal."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/01.RES.0000215576.27615.fd","article-title":"Role of nuclear Ca2+\/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival","volume":"98","author":"Nagel","year":"2025","journal-title":"Circ. Res."},{"key":"ref_150","first-page":"135","article-title":"From age-related cognitive decline to Alzheimer's disease: A translational overview of the potential role for phosphodiesterases","volume":"Volume 17","author":"Zhang","year":"2017","journal-title":"Phosphodiesterases: CNS Functions and Diseases. Advances in Neurobiology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/ADR-200191","article-title":"Phosphodiesterase Inhibitors for Alzheimer\u2019s Disease: A systematic review of clinical trials and epidemiology with a mechanistic rationale","volume":"4","author":"Sanders","year":"2020","journal-title":"J. Alzheimer\u2019s Dis. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neulet.2010.02.046","article-title":"Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation","volume":"473","author":"Filgueiras","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijdevneu.2012.05.001","article-title":"Early alcohol exposure disrupts visual cortex plasticity in mice","volume":"30","author":"Lantz","year":"2012","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Krahe, T.E., Wang, W., and Medina, A.E. (2009). Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006643"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2011.05.024","article-title":"Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder","volume":"119","author":"Nunes","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Araujo, U.C., Nunes, F., Goncalves, B.S., Gomes, R.A.A., Moreira, M.F.R., Nunes-Freitas, A., Krahe, T., de Abreu-Villaca, Y., Manhaes, A.C., and Filgueiras, C.C. (2025). Vinpocetine, a phosphodiesterase type 1 inhibitor, mitigates locomotor hyperactivity in female mice exposed to lead during development. Brain Sci., 15.","DOI":"10.3390\/brainsci15020150"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"35","DOI":"10.55782\/ane-2022-004","article-title":"Vinpocetine ameliorates developmental hyperserotonemia induced behavioral and biochemical changes: Role of neuronal function, inflammation, and oxidative stress","volume":"82","author":"Luhach","year":"2022","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.alcohol.2022.08.005","article-title":"Vinpocetine, a PDE1 modulator, regulates markers of cerebral health, inflammation, and oxidative stress in a rat model of prenatal alcohol-induced experimental attention deficit hyperactivity disorder","volume":"105","author":"Sharma","year":"2022","journal-title":"Alcohol"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"6361703","DOI":"10.1155\/2020\/6361703","article-title":"Preconditioning with PDE1 inhibitors and moderate-intensity training positively affect systemic redox state of rats","volume":"2020","author":"Ristic","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"112512","DOI":"10.1016\/j.bbr.2020.112512","article-title":"The protective and therapeutic effects of vinpocetine, a PDE1 inhibitor, on oxidative stress and learning and memory impairment induced by an intracerebroventricular (ICV) injection of amyloid beta (a\u00df) peptide","volume":"383","author":"Shekarian","year":"2020","journal-title":"Behav. Brain Res."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Shekarian, M., Saleji, I., Raoufdi, S., Asadbegi, M., Kourosh-Arami, M., and Komaki, A. (2023). Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer's disease. BMC Neurosci., 24.","DOI":"10.1186\/s12868-023-00790-8"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2014.03.032","article-title":"Protective effects of phosphodiesterase-1 and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease","volume":"732","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_163","first-page":"108","article-title":"Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability","volume":"42","author":"Hayakawa","year":"1992","journal-title":"Arzneim. Forsch."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Goksel, E., Ugurel, E., Nader, E., Boisson, C., Muniansi, I., Joly, P., Renoux, C., Gauthier, A., Connes, P., and Yalcin, O. (2023). A preliminary study of phosphodiesterases and adenylyl cyclase signaling pathway on red blood cell deformability of sickle cell patients. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1215835"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tips.2005.08.004","article-title":"Adenosine receptor signaling in the brain immune system","volume":"26","author":"Hasko","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neuroscience.2007.07.035","article-title":"Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus","volume":"149","author":"Sperlagh","year":"2007","journal-title":"Neuroscience"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Salmaso, V., Menin, S., Moro, S., Spalluto, G., and Federico, S. (2025). Adenosine receptors in neuroinflammation and neurodegeneration. Cells, 14.","DOI":"10.3390\/cells14201585"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Effendi, W.I., Nagano, T., Kobayashi, K., and Nishimura, Y. (2020). Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells, 9.","DOI":"10.3390\/cells9030785"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0773.1983.tb01131.x","article-title":"The effect of some drugs with purported antianoxic effect on veratridine-induced purine release from isolated rat hypothalamic synaptosomes","volume":"53","author":"Fredholm","year":"1983","journal-title":"Acta Pharmacol. Toxicol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0361-9230(90)90091-D","article-title":"Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue","volume":"24","author":"Milusheva","year":"1990","journal-title":"Brain Res. Bull."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-2999(91)90762-F","article-title":"Vinpocetine increases the neuroprotective effect of adenosine in vitro","volume":"205","author":"Krieglstein","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40261-016-0415-x","article-title":"Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: A randomized, open-label, controlled, multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) trial","volume":"36","author":"Zhang","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, M., Jiang, Y., and Ji, Q. (2004). Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: A network meta-analysis. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1530987"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4103\/2141-9248.139368","article-title":"Effect of vinpocetine (cognitol) on cognitive performances of a nigerian population","volume":"4","author":"Ogunrin","year":"2014","journal-title":"Ann. Med. Health Sci. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0253-7613.201037","article-title":"Is aura around citicoline fading? A systemic review","volume":"49","author":"Agarwal","year":"2017","journal-title":"Indian J. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10072-017-3214-0","article-title":"Safety and efficacy of Cerebrolysin in early post-stroke recovery: A meta-analysis of nine randomized clinical trials","volume":"39","author":"Bornstein","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e37593","DOI":"10.1097\/MD.0000000000037593","article-title":"Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment","volume":"103","author":"Wan","year":"2024","journal-title":"Medicine"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00415-018-8935-3","article-title":"Minocycline for acute stroke treatment: A systematic review and meta-analysis of randomized clinical trials","volume":"265","author":"Malhotra","year":"2018","journal-title":"J. Neurol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/3\/454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:26:13Z","timestamp":1773764773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/3\/454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":179,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["biom16030454"],"URL":"https:\/\/doi.org\/10.3390\/biom16030454","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}